Kallikrein Inhibitor

Kallikrein Inhibitors (20):

Cat. No.	Product Name	Effect	Purity

HY-16735

Avoralstat	Inhibitor	≥98.0%
Avoralstat (BCX4161), a potent and orally active plasma kallikrein (PKK) inhibitor, is used for hereditary angioedema research.

HY-109127A

Berotralstat dihydrochloride	Inhibitor	98.49%
Berotralstat dihydrochloride is a low toxicity, effective, highly specific, second-generation, synthetic and orally active plasma kallikrein inhibitor used for the research of hereditary angioedema (HAE) attacks. Berotralstat dihydrochloride works by blocking the enzymatic activity of plasma kallikrein in releasing bradykinin, the major biologic peptide that promotes swelling and pain associated with attacks of HAE.

HY-132830

Sebetralstat	Inhibitor	99.58%
Sebetralstat (KVD900) is a plasma kallikrein inhibitor (WO2016083820). Sebetralstat can be used for the research of metabolic diseases.

HY-109127

Berotralstat	Inhibitor	99.70%
Berotralstat (BCX7353) is an orally active plasma kallikrein inhibitor. Berotralstat can reduce brain edema and is being studied for glioblastoma and hereditary angioedema.

HY-P99110

Lanadelumab	Inhibitor
Lanadelumab (SHP643) is a human IgG1 monoclonal antibody against plasma kallikrein (pKal) with an K_i value of 0.12 nM. Lanadelumab inhibits both free and HMWK (high molecular weight kininogen)-bound pKal. Lanadelumab has the potential for the research of hereditary angioedema.

HY-148949A

Kallikrein 5-IN-2 TFA	Inhibitor
Kallikrein 5-IN-2 TFA is the TFA salt form of Kallikrein 5-IN-2 (HY-148949). Kallikrein 5-IN-2 TFA is a selective inhibitor for kallikrein 5 (KLK5) with pIC₅₀ of 7.1. Kallikrein 5-IN-2 TFA is non-phototoxic (100 μg/mL) and non-irritant. Kallikrein 5-IN-2 is stable at pH 4-pH 8 under non-oxidative condition. Kallikrein 5-IN-2 is potent in ameliorating the Netherton syndrome.

HY-163464

Plasma kallikrein-IN-5	Inhibitor
Plasma kallikrein-IN-5 (Compound 20) is a potent covalent inhibitor of plasma potassium kinin peptide (Pka) with IC₅₀ values of 66 nM and 70 pM at 1 minute and 24 hours, respectively. Plasma kallikrein-IN-5 can be used IN the study of hereditary angioedema (HAE).

HY-123133

PKSI-527	Inhibitor	98.08%
PKSI-527 is a new, highly selective plasma kallikrein inhibitor. PKSI-527 can suppress collagen-induced arthritis (CIA) by modifying the kallikrein-kinin system.

HY-108814A

Ecallantide TFA	Inhibitor	98.63%
Ecallantide (DX-88) TFA is a specific recombinant plasma kallikrein inhibitor. Ecallantide inhibits the production of bradykinin. Ecallantide may be used to prevent acute attacks of angioedema.

HY-P4245

D-Pro-Phe-Arg-Chloromethylketone	Inhibitor	98.95%
D-Pro-Phe-Arg-Chloromethylketone, a inhibitor of coagulation factor XII and plasma kallikrein, plays an important role in thrombosis and inflammation.

HY-145568

Feniralstat	Inhibitor	99.87%
Feniralstat (compound 30), a pyrazole derivative, is a potent kallikrein inhibitor with an IC₅₀ of 6.7 nM for Human plasma kallikrein (pKal). Feniralstat has no inhibition on Human KLKl, Human FXIa, Human Factor Xlla (all IC₅₀>40 μM).

HY-122543

PPACK II diTFA	Inhibitor
PPACK II diTFA is an irreversible and specific glandular and plasma kallikreins inhibitor.

HY-126378

LSP-249	Inhibitor	99.05%
LSP-249 (example 35), extracted from patent WO2016011209A1, is a plasma kallikrein inhibitor under the study for angioedema, with an EC₅₀ less than 100 nM in cell.

HY-153115

Plasma kallikrein-IN-4	Inhibitor	98.61%
Plasma kallikrein-IN-4 (Example 153) is a plasma kallikrein inhibitor with an IC₅₀ of 0.016 μM against human plasma kallikrein.

HY-139888

Plasma kallikrein-IN-1	Inhibitor
Plasma kallikrein-IN-1 is a PKK inhibitor with an IC₅₀ value of 0.5 nM.

HY-108814

Ecallantide	Inhibitor
Ecallantide (DX-88) is a specific plasma kallikrein inhibitor. Ecallantide inhibits the production of bradykinin. Ecallantide can be used to prevent acute attacks of angioedema.

HY-122543A

PPACK II	Inhibitor
PPACK II is an irreversible and specific glandular and plasma kallikreins inhibitor.

HY-143476

Plasma kallikrein-IN-2	Inhibitor
Plasma kallikrein-IN-2 (Compound 198) is a potent plasma kallikrein (PKal) inhibitor with an IC₅₀ of 0.1 nM. Plasma kallikrein-IN-2 can be used for hereditary angioedema, diabetic macular edema, and diabetic retinopathy research.

HY-150052

Plasma kallikrein-IN-3	Inhibitor
Plasma kallikrein-IN-3 is a plasma kallikrein inhibitor (IC₅₀: 0.15 μM). Plasma kallikrein-IN-3 can be used for hereditary angioedema, diabetic macular edema, and diabetic retinopathy research.

HY-19101

ONO-3307	Inhibitor
ONO-3307 is a protease inhibitor that competitively inhibits a variety of proteases including trypsin, thrombin, plasma kallikrein, plasmin, pancreatic kallikrein, and chymotrypsin. ONO-3307 alleviates endotoxin-induced experimental disseminated intravascular coagulation (DIC) in rats. ONO-3307 can be used in the study of thrombosis and protease-mediated diseases.

Name
Email *

	Sorry, but the email address you supplied was invalid.